W. T. London and K. A. Mcglynn, Liver cancer, pp.763-786, 2006.

I. Ahmed and D. N. Lobo, Malignant tumours of the liver, Surgery (Oxford), vol.27, issue.1, pp.30-37, 2009.

L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, and J. Lortettieulent, CA: A Cancer Journal for Clinicians, vol.65, issue.2, pp.87-108, 2012.

, BioMed Research International 9

R. X. Zhu, W. Seto, C. Lai, and M. Yuen, Epidemiology of hepatocellular carcinoma in the Asia-Pacific region, Gut and Liver, vol.10, issue.3, pp.332-339, 2016.

M. Plummer, C. Martel, J. Vignat, J. Ferlay, F. Bray et al., Global burden of cancers attributable to infections in 2012: a synthetic analysis, The Lancet Global Health, vol.4, issue.9, pp.609-616, 2016.

C. Martel, D. Maucort-boulch, M. Plummer, and S. Franceschi, World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma, Hepatology, vol.62, issue.4, pp.1190-1200, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02044957

G. S. Bhattacharyya, K. Babu, H. Malhotra, A. A. Ranade, S. Murshed et al., Hepatocellular carcinoma in India, Chinese Clinical Oncology, vol.2, issue.4, 2013.

G. Baffy, E. M. Brunt, and S. H. Caldwell, Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace, Journal of Hepatology, vol.56, issue.6, pp.1384-1391, 2012.

G. Bertino, S. Demma, and A. Ardiri, Hepatocellular carcinoma: Novel molecular targets in carcinogenesis for future therapies, BioMed Research International, vol.2014, 2014.

N. Goutté, P. Sogni, N. Bendersky, J. C. Barbare, B. Falissard et al., Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country, Journal of Hepatology, vol.66, issue.3, pp.537-544, 2017.

M. Schwartz, S. Roayaie, and M. Konstadoulakis, Strategies for the management of hepatocellular carcinoma, Nature Clinical Practice Oncology, vol.4, issue.7, pp.424-432, 2007.

M. B. Thomas and A. X. Zhu, Hepatocellular carcinoma: The need for progress, Journal of Clinical Oncology, vol.23, issue.13, pp.2892-2899, 2005.

S. Subramanian, R. K. Kelly, and A. P. Venook, A review of hepatocellular carcinoma (HCC) staging systems, Chinese Clinical Oncology, vol.2, issue.4, pp.33-44, 2013.

F. K. Keane, J. Y. Wo, A. X. Zhu, and T. S. Hong, Liver-Directed Radiotherapy for Hepatocellular Carcinoma, Liver Cancer, vol.5, issue.3, pp.198-209, 2016.

R. Gallicchio, A. Nardelli, and P. Mainenti, Therapeutic strategies in HCC: Radiation modalities, BioMed Research International, vol.2016, 2016.

M. A. Wörns, A. Weinmann, M. Schuchmann, and P. R. Galle, Systemic therapies in hepatocellular carcinoma, Digestive Diseases, vol.27, issue.2, pp.175-188, 2009.

C. A. Arciero and E. R. Sigurdson, Liver-directed therapies for patients with primary liver cancer and hepatic metastases, Current Treatment Options in Oncology, vol.7, issue.5, pp.399-409, 2006.

S. Medavaram and Y. Zhang, Emerging therapies in advanced hepatocellular carcinoma, Experimental Hematology and Oncology, vol.7, issue.77, 2018.

J. Raoul, M. Kudo, R. S. Finn, J. Edeline, M. Reig et al., Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond, Cancer Treatment Reviews, vol.68, pp.16-24, 2018.

M. Ronot, A. K. Clift, V. Vilgrain, and A. Frilling, Functional imaging in liver tumours, Journal of Hepatology, vol.65, issue.5, pp.1017-1030, 2016.

A. J. Page, M. J. Weiss, and T. M. Pawlik, Surgical management of noncolorectal cancer liver metastases, Cancer, vol.120, issue.20, pp.3111-3121, 2014.

R. Fernandez, S. G. Pappas, and D. J. Bentrem, Clinical Features of Metastatic Hepatic Malignancies, Cancer Treatment and Research, vol.168, pp.185-202, 2016.

M. G. Zampino, E. Magni, and P. S. Ravenda, Treatments for colorectal liver metastases: A new focus on a familiar concept, Critical Review in Oncology/Hematology, vol.108, pp.154-163, 2016.

A. Filice, A. Fraternali, and A. Frasoldati, Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: A single centre experience, Journal of Oncology, 2012.

S. P. Thang, M. S. Lung, and G. Kong, Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) -a single-institution retrospective analysis, European Journal of Nuclear Medicine and Molecular Imaging, vol.45, issue.2, pp.262-277, 2018.

K. I. Alexandraki, A. Karapanagioti, I. Karoumpalis, G. Boutzios, and G. A. Kaltsas, Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms, BioMed Research International, vol.2017, 2017.

P. Giunchedi, M. Maestri, E. Gavini, P. Dionigi, and G. Rassu, Transarterial chemoembolization of hepatocellular carcinoma-agents and drugs: An overview. Part 2, Expert Opinion on Drug Delivery, vol.10, issue.6, pp.799-810, 2013.

K. Burak and N. Kneteman, An Evidence-Based Multidisciplinary Approach to the Management of Hepatocellular Carcinoma (HCC): The Alberta HCC Algorithm, Canadian Journal of Gastroenterology & Hepatology, vol.24, 2010.

M. F. Bozkurt, B. V. Salanci, and . U?ur, Intra-arterial radionuclide therapies for liver tumors, Seminars in Nuclear Medicine, vol.46, issue.4, pp.324-339, 2016.

P. Hilgard, S. Müller, and M. Hamami, Selective internal radiotherapy (radioembolization) and radiation therapy for HCC -Current status and perspectives, Zeitschrift für Gastroenterologie, vol.47, issue.1, pp.37-54, 2009.

J. Raoul, E. Boucher, Y. Rolland, and E. Garin, Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides, Nature Reviews Gastroenterology & Hepatology, vol.7, issue.1, pp.41-49, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00742471

J. Burrill, U. Häfeli, and D. M. Liu, Advances in radioembolization -embolics and isotopes, Journal of Nuclear Medicine Radiation Therapy, vol.2, issue.1, pp.107-112, 2011.

R. Salem and K. G. Thurston, Radioembolization with yttrium-90 microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies -Part 3: Comprehensive literature review and future direction, Journal of Vascular and Interventional Radiology, vol.17, issue.10, pp.1571-1593, 2006.

N. Khajornjiraphan, N. A. Thu, and P. K. Chow, Yttrium-90 microspheres: a review of its emerging clinical indications, Liver Cancer, vol.4, issue.1, pp.6-15, 2015.

J. R. Kallini, A. Gabr, R. Salem, and R. J. Lewandowski, Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma, Advances in Therapy, vol.33, issue.5, pp.699-714, 2016.

B. S. Sangha, H. Nimeiri, R. Hickey, R. Salem, and R. J. Lewandowski, Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?, Current Treatment Options in Oncology, vol.17, issue.6, 2016.

V. Vilgrain, H. Pereira, and E. Assenat, Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, The Lancet Oncology, vol.18, issue.12, pp.1624-1636, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01727346

E. D. Grady, Internal radiation therapy of hepatic cancer, Diseases of the Colon & Rectum, vol.22, pp.371-375, 1979.

M. A. Westcott, D. M. Coldwell, D. M. Liu, and J. F. Zikria, The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres, Advances in Radiation Oncology, vol.1, issue.4, pp.351-364, 2016.

J. F. Nijsen, A. D. Van-het-schip, W. E. Hennink, D. W. Rook, P. P. Van-rijk et al., Advances in nuclear oncology: Microspheres for internal radionuclide therapy in liver tumours, Current Medicinal Chemistry, vol.9, issue.1, pp.73-82, 2002.

L. Caldarola, U. Rosa, F. Badellino, S. Sosi, and A. Cavalli, Preparation of 32-p labelled resin microspheres for radiation treatment of tumours by intra-arterial injection, Minerva nucleare, vol.55, pp.169-174, 1964.

S. Vinjamuri and S. Ray, Phosphorus-32: the forgotten radiopharmaceutical?, Nuclear Medicine Communications, vol.29, issue.2, pp.95-97, 2008.

L. Yan, Z. Li, and L. Li, The relationship between effects and radiation doses of intra-arterial phosphorus-32 glass microspheres embolization therapy for patients with advanced liver cancer, Chinese journal of surgery, vol.38, issue.11, pp.837-840, 2000.

E. Pirayesh, M. Amoui, and S. Akhlaghpoor, Technical Considerations of Phosphorous-32 Bremsstrahlung SPECT Imaging after Radioembolization of Hepatic Tumors: A Clinical Assessment with a Review of Imaging Parameters, Radiology Research and Practice, vol.2014, 2014.

P. R. Seevinck, G. H. Van-de-maat, T. C. De-wit, M. A. Vente, J. F. Nijsen et al., Magnetic resonance imaging-based radiation-absorbed dose estimation of166Ho microspheres in liver radioembolization, International Journal of Radiation Oncology Biology Physics, vol.83, issue.3, pp.437-444, 2012.

G. H. Van-de-maat, P. R. Seevinck, C. Bos, and C. J. Bakker, Quantification of holmium-166 loaded microspheres: Estimating high local concentrations using a conventional multiple gradient echo sequence with S 0-fitting, Journal of Magnetic Resonance Imaging, vol.35, issue.6, pp.1453-1461, 2012.

M. A. Vente, J. F. Nijsen, and R. De-roos, Neutron activation of holmium poly(L-lactic acid) microspheres for hepatic arterial radioembolization: A validation study, Biomedical Microdevices, vol.11, issue.4, pp.763-772, 2009.

R. J. Mumper and M. Jay, Biodegradable radiotherapeutic polyester microspheres: optimization and in-vitro/in-vivo evaluation, Journal of Controlled Release, vol.18, issue.3, pp.193-203, 1992.

S. W. Zeilhuis, J. H. Seppenwoolde, and C. J. Bakker, Characterization of holmium loaded alginate microspheres for multimodality imaging and therapeutic applications, Journal of Biomedical Materials Research Part A, vol.82, issue.4, pp.892-898, 2007.

A. Arranja, W. Hennink, A. Denkova, R. Hendrikx, and J. Nijsen, Radioactive holmium phosphate microspheres for cancer treatment, International Journal of Pharmaceutics, vol.548, issue.1, pp.73-81, 2018.

J. H. Turner, P. G. Claringbold, and P. F. Klemp, 166 Homicrosphere liver radiotherapy: A preclinical SPECT dosimetry study in the pig, Nuclear Medicine Communications, vol.15, issue.7, pp.545-553, 1994.

R. F. Costa, M. Mb, N. Nascimento, F. F. Sene-martinelli, and J. A. Osso, Production of microspheres labeled with holmium-166 for liver cancer therapy: the preliminary experience at IPEN-CNEN/SP, Proceedings of the International Nuclear Atlantic Conference -INAC, 2009.

G. J. Ehrhardt and D. E. Day, Therapeutic use of 90Y microspheres, International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, vol.14, issue.3, pp.233-242, 1987.

R. F. Brown, L. C. Lindesmith, and D. E. Day, 166Holmium-containing glass for internal radiotherapy of tumors, International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, vol.18, issue.7, pp.783-790, 1991.

P. A. Schubiger, H. Beer, and L. Geiger, 90Y-resin particlesAnimal experiments on pigs with regard to the introduction of superselective embolization therapy, International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, vol.18, issue.3, pp.305-311, 1991.

S. Subramanian, K. V. Vimalnath, and A. Dash, Preparation and preliminary in vivo evaluation of 166Ho-labeled microspheres for possible use in radioembolic therapy of liver cancer, Journal of Labelled Compounds and Radiopharmaceuticals, vol.61, issue.6, pp.509-514, 2018.

R. J. Mumper and M. Jay, Poly(L-lactic Acid) Microspheres Containing Neutron-Activatable Holmium-165: A Study of the Physical Characteristics of Microspheres Before and After Irradiation in a Nuclear Reactor, Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists, vol.9, issue.1, pp.149-154, 1992.

S. W. Zielhuis, J. F. Nijsen, and R. Figueiredo, Surface characteristics of holmium-loaded poly(L-lactic acid) microspheres, Biomaterials, vol.26, issue.8, pp.925-932, 2005.

Y. S. Suzuki, Y. Momose, and N. Higashi, Biodistribution and kinetics of holmium-166-chitosan complex (DW-166HC) in rats and mice, Journal of Nuclear Medicine, vol.39, issue.12, pp.2161-2166, 1998.

J. F. Nijsen, B. A. Zonnenberg, and J. R. Woittiez, Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: Effects of preparation and neutron activation techniques, European Journal of Nuclear Medicine and Molecular Imaging, vol.26, issue.7, pp.699-704, 1999.

R. J. Mumper and M. Jay, Formation and stability of lanthanide complexes and their encapsulation into polymeric microspheres, The Journal of Physical Chemistry C, vol.96, issue.21, pp.8626-8631, 1992.

R. J. Mumper, U. Y. Ryo, and M. Jay, Neutron-activated holmium-166-Poly(L-lactic acid) microspheres: A potential agent for the internal radiation therapy of hepatic tumors, Journal of Nuclear Medicine, vol.32, issue.11, pp.2139-2143, 1991.

S. W. Zielhuis, J. F. Nijsen, L. Dorland, G. C. Krijger, A. D. Van-het-schip et al., Removal of chloroform from biodegradable therapeutic microspheres by radiolysis, International Journal of Pharmaceutics, vol.315, issue.1-2, pp.67-74, 2006.

W. Bult, R. Varkevisser, and F. Soulimani, Holmium nanoparticles: Preparation and in vitro characterization of a new device for radioablation of solid malignancies, Pharmaceutical Research, vol.27, issue.10, pp.2205-2212, 2010.

S. W. Zielhuis, J. F. Nijsen, G. C. Krijger, A. D. Van-het-schip, and W. E. Hennink, Holmium-loaded poly(L-lactic acid) microspheres: In vitro degradation study, Biomacromolecules, vol.7, issue.7, pp.2217-2223, 2006.

S. W. Zielhuis, J. F. Nijsen, and R. De-roos, Production of GMP-grade radioactive holmium loaded poly(L-lactic acid) microspheres for clinical application, International Journal of Pharmaceutics, vol.311, issue.1-2, pp.69-74, 2006.

F. Nijsen, D. Rook, and C. Brandt, Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: A biodistribution study, European Journal of Nuclear Medicine and Molecular Imaging, vol.28, issue.6, pp.743-749, 2001.

S. W. Zielhuis, J. F. Nijsen, and J. Seppenwoolde, Longterm toxicity of holmium-loaded poly(l-lactic acid) microspheres in rats, Biomaterials, vol.28, issue.31, pp.4591-4599, 2007.

M. A. Vente, J. F. Nijsen, and T. C. De-wit, Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L-lactic acid) microspheres in healthy pigs, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.7, pp.1259-1271, 2008.

J. F. Nijsen, J. Seppenwoolde, T. Havenith, C. Bos, C. J. Bakker et al., Liver Tumors: MR Imaging of Radioactive Holmium Microspheres -Phantom and Rabbit Study, vol.231, pp.491-499, 2004.

J. Seppenwoolde, J. F. Nijsen, L. W. Bartels, S. W. Zielhuis, A. D. Van-het et al., Internal radiation therapy of liver tumors: Qualitative and quantitative magnetic resonance imaging of the biodistribution of holmiumloaded microspheres in animal models, Magnetic Resonance in Medicine, vol.53, issue.1, pp.76-84, 2005.

M. A. Vente, T. C. De-wit, M. A. Van-den, and . Bosch, Holmium-166 poly(L-lactic acid) microsphere radioembolisation of the liver: Technical aspects studied in a large animal model, European Radiology, vol.20, issue.4, pp.862-869, 2010.

M. L. Smits, J. F. Nijsen, M. A. Van-den, and . Bosch, Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial, Journal of Experimental & Clinical Cancer Research, vol.29, issue.70, 2010.

M. L. Smits, J. F. Nijsen, M. A. Van-den, and . Bosch, Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): A phase 1, dose-escalation study, The Lancet Oncology, vol.13, issue.10, pp.1025-1034, 2012.

M. L. Smits, M. Elschot, M. A. Van-den, and . Bosch, In vivo dosimetry based on SPECT and MR imaging of 166Ho-microspheres for treatment of liver malignancies, Journal of Nuclear Medicine, vol.54, issue.12, pp.2093-2100, 2013.

M. Elschot, J. F. Nijsen, and M. G. Lam, 99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Ho-microspheres, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, issue.10, pp.1965-1975, 2014.

J. F. Prince, R. Van-rooij, G. H. Bol, H. W. Jong, M. A. Van-den et al., Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres, Journal of Nuclear Medicine, vol.56, issue.6, pp.817-823, 2015.

J. F. Prince, M. A. Van-den, J. F. Bosch, and . Nijsen, Efficacy of radioembolization with 166Ho-Microspheres in salvage patients with liver metastases: A phase 2 study, Journal of Nuclear Medicine, vol.59, issue.4, pp.582-588, 2018.

J. F. Prince, M. L. Smits, and G. C. Krijger, Radiation emission from patients treated with holmium-166 radioembolization, Journal of Vascular and Interventional Radiology, vol.25, issue.12, pp.1956-1963, 2014.

A. F. Van-den-hoven, J. F. Prince, and R. C. Bruijnen, Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: Study protocol for a randomized controlled trial, Trials, vol.17, issue.1, 2016.

J. K. Kim, K. Han, and J. T. Lee, Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (milican) for the treatment of small hepatocellular carcinoma, Clinical Cancer Research, vol.12, issue.2, pp.543-548, 2006.

J. H. Sohn, H. J. Choi, and J. T. Lee, Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma, Oncology, vol.76, issue.1, pp.1-9, 2008.

M. Argyrou, A. Valassi, M. Andreou, and M. Lyra, Rhenium-188 Production in Hospitals

, Generator, for Easy Use in Radionuclide Therapy, Article ID 290750, 7 pages, vol.2013, 2013.

F. Knapp, Continued Availability of the Tungsten-188/ Rhenium-188 Generator to Enhance Therapeutic Utility of 188Re, International Journal of Nuclear Medicine Research, 2017.

G. Wunderlich, J. Pinkert, M. Stintz, and J. Kotzerke, Labeling and biodistribution of different particle materials for radioembolization therapy with 188Re, Applied Radiation and Isotopes, vol.62, issue.5, pp.745-750, 2005.

S. D. Conzone, U. O. Häfeli, D. E. Day, and G. J. Ehrhardt, Preparation and properties of radioactive rhenium glass microspheres intended for in vivo radioembolization therapy, Journal of Biomedical Materials Research Part B: Applied Biomaterials, vol.42, issue.4, pp.617-625, 1998.

U. O. Häfeli, S. Casillas, and D. W. Dietz, Hepatic tumor radioembolization in a rat model using radioactive rhenium (186RE/188RE) glass microspheres, International Journal of Radiation Oncology Biology Physics, vol.44, issue.1, pp.189-199, 1999.

S. Wang, W. Lin, and M. Chen, Intratumoral injection of rhenium-188 microspheres into an animal model of hepatoma, Journal of Nuclear Medicine, vol.39, issue.10, pp.1752-1757, 1998.

Y. Lin, S. Tsai, G. Hung, J. Lee, Y. Huang et al., Direct injection of 188Re-microspheres in the treatment of hepatocellular carcinoma. Compared with traditional percutaneous ethanol injection: An animal study, Nuklearmedizin / Nuclear Medicine, vol.44, issue.3, pp.76-80, 2005.

U. O. Häfeli, W. K. Roberts, G. J. Pauer, S. Kraeft, and R. M. Macklis, Stability of biodegradable radioactive rhenium (Re-186 and Re-188) microspheres after neutron-activation, Applied Radiation and Isotopes, vol.54, issue.6, pp.869-879, 2001.

J. Shukla, G. P. Bandopadhyaya, and I. K. Varma, 188Rhe-nium(V)-dimercaptosuccinic acid loaded poly(lactic-co-glycolic)acid microspheres for targeted radiotherapy: Production and effectivity, Die Pharmazie, vol.60, issue.8, pp.583-587, 2005.

J. Yu, U. O. Häfeli, and J. Xia, Radiolabelling of poly(histidine) derivatized biodegradable microspheres with the 188Re tricarbonyl complex, Nuclear Medicine Communications, vol.26, issue.5, pp.453-458, 2005.

M. Jamre, M. Shamsaei, M. Erfani, S. Sadjadi, and M. Ghannadi-maragheh, Preparation and evaluation of, Journal of Labelled Compounds and Radiopharmaceuticals, vol.61, issue.8, pp.586-594, 2018.

P. Chiang, C. Peng, and Y. Shih, Biodegradable and Multifunctional Microspheres for Treatment of Hepatoma through Transarterial Embolization, ACS Biomaterials Science & Engineering, vol.4, issue.9, pp.3425-3433, 2018.

C. Meyer, C. C. Pieper, S. Ezziddin, K. E. Wilhelm, H. H. Schild et al., Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, issue.2, pp.231-237, 2014.

E. Verger, P. Drion, and G. Meffre, 68Ga and 188Re starchbased microparticles as theranostic tool for the hepatocellular carcinoma: Radiolabeling and preliminary in vivo rat studies, PLoS ONE, vol.11, issue.10, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01398433

E. Garin, E. Boucher, and Y. Rolland, 99mTc-MAA-based dosimetry for liver cancer treated using 90Y-loaded microspheres: Known proof of effectiveness, Journal of Nuclear Medicine, vol.55, issue.8, pp.1391-1392, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01175542

G. Wunderlich, J. Pinkert, and M. Andreeff, Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: A promising new agent for radiotherapy, Applied Radiation and Isotopes, vol.52, issue.1, pp.63-68, 2000.

G. Wunderlich, A. Drews, and J. Kotzerke, A kit for labeling of [188Re] human serum albumin microspheres for therapeutic use in nuclear medicine, Applied Radiation and Isotopes, vol.62, issue.6, pp.915-918, 2005.

L. Chen, Y. Chang, and S. Chen, Imaging, biodistribution and efficacy evaluation of 188Re-human serum albumin microspheres via intraarterial route in an orthotopic hepatoma model, International Journal of Radiation Biology, vol.93, issue.5, pp.477-486, 2017.

K. Liepe, C. Brogsitter, and J. Leonhard, Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization, Japanese Journal of Clinical Oncology, vol.37, issue.12, pp.942-950, 2007.

M. L. Nowicki, J. B. ?wik?a, and A. J. Sankowski, Initial study of radiological and clinical efficacy radioembolization using 188re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers, Medical Science Monitor, vol.20, pp.1353-1362, 2014.

K. Nakakuma, S. Tashiro, T. Hiraoka, K. Ogata, and K. Ootsuka, Hepatocellular carcinoma and metastatic cancer detected by iodized oil, Radiology, vol.154, issue.1, pp.15-17, 1985.

N. C. Fairlie and A. N. Adam, Case report: Persistence of lipiodol for 13 months in metastatic deposits in the liver on computed tomography, Clinical Radiology, vol.44, issue.4, pp.273-274, 1991.

J. Liebster and V. Ko?andrle, Exchange labelling of 'lipiodol' ultra fluids with lodine-131 and its intra-lymphatic administration with a fistula on the thoracic duct, Nature, vol.203, issue.4946, pp.777-778, 1964.

A. Lintia-gaultier, C. Perret, C. Ansquer, T. Eugène, F. Kraeberbodéré et al., Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience, Nuclear Medicine Communications, vol.34, issue.7, pp.674-681, 2013.

J. Raoul, E. Boucher, Y. Roland, and E. Garin, 131-iodine Lipiodol therapy in hepatocellular carcinoma, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol.53, issue.3, pp.348-355, 2009.

M. T. Madsen, C. H. Park, and M. L. Thakur, Dosimetry of iodine-131 ethiodol in the treatment of hepatoma, Journal of Nuclear Medicine, vol.29, issue.6, pp.1038-1044, 1988.

B. Lambert, K. Bacher, and L. Defreyne, Rhenium-188 based radiopharmaceuticals for treatment of liver tumours, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol.53, issue.3, pp.305-310, 2009.

N. Lepareur, Transarterial Radionuclide Therapy with 188Re-Labelled Lipiodol, International Journal of Nuclear Medicine Research, 2017.

S. Wang, W. Lin, and M. Chen, Radiolabelling of Lipiodol with generator-produced 188Re for hepatic tumor therapy, Applied Radiation and Isotopes, vol.47, issue.3, pp.267-271, 1996.

S. Wang, W. Lin, and M. Chen, Biodistribution of rhenium-188 Lipiodol infused via the hepatic artery of rats with hepatic tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.23, issue.1, pp.13-17, 1996.

S. Wang, W. Lin, W. Lui, M. Chen, Z. Tsai et al., Hepatic artery injection of yttrium-90-lipiodol: biodistribution in rats with hepatoma, Journal of Nuclear Medicine, vol.37, issue.2, pp.332-335, 1996.

T. W. Jackson, M. Kojima, and R. M. Lambrecht, Rhenium Diamino Dithiol Complexes. III. Lipophilic Ligands for Endotherapeutic Radiopharmaceuticals, Australian Journal of Chemistry, vol.53, issue.12, p.983, 2000.

J. M. Jeong, Y. J. Kim, and Y. S. Lee, Lipiodol solution of a lipophilic agent, 188 Re-TDD, for the treatment of liver cancer, Nuclear Medicine and Biology, vol.28, issue.2, pp.197-204, 2001.

Y. Lee, J. M. Jeong, and Y. J. Kim, Synthesis of 188Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer, Nuclear Medicine Communications, vol.23, issue.3, pp.237-242, 2002.

J. C. Paeng, J. M. Jeong, and C. J. Yoon, Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: Preclinical study in a rabbit liver cancer model, Journal of Nuclear Medicine, vol.44, issue.12, pp.2033-2038, 2003.

Y. Lee, J. M. Jeong, and Y. Kim, Development of acetylated HDD kit for preparation of 188Re-HDD/lipiodol, Applied Radiation and Isotopes, vol.65, issue.1, pp.64-69, 2007.

V. K. Banka, S. Moon, and J. M. Jeong, Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent, p.188

. Hdd/lipiodol, Nuclear Medicine and Biology, vol.42, issue.3, pp.317-322, 2015.

T. Luo, B. Hsieh, and S. Wang, Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection, Nuclear Medicine and Biology, vol.31, issue.5, pp.671-677, 2004.

T. Luo, Y. Shih, and C. Chen, Evaluating the potential of 188re-ecd/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment, Cancer Biotherapy and Radiopharmaceuticals, vol.24, issue.5, pp.535-541, 2009.

G. Wang, J. Zhang, and S. Luo, Synthesis and primary biological evaluation of 188ReN-NEMPTDD, Journal of Radioanalytical and Nuclear Chemistry, vol.277, issue.2, pp.365-369, 2008.

I. Tang, T. Luo, and S. Liu, Synthesis and application of 188Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model, Nuclear Medicine and Biology, vol.38, issue.7, pp.1043-1052, 2011.

P. Huang, S. Tsai, T. Luo, C. Kao, and W. Lin, Therapeutic efficacy of 188Re-MN-16ET lipiodol in an animal model of hepatocellular carcinoma, Annals of Nuclear Medicine, vol.27, issue.6, pp.532-537, 2013.

A. Boschi, L. Uccelli, and A. Duatti, A kit formulation for the preparation of re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma, Nuclear Medicine Communications, vol.25, issue.7, pp.691-699, 2004.

N. Lepareur, E. Garin, N. Noiret, and J. Y. Herry, A kit formulation for the labelling of lipiodol with generator-produced 188Re, Journal of Labelled Compounds and Radiopharmaceuticals, vol.47, issue.12, pp.857-867, 2004.

N. Lepareur, V. Ardisson, N. Noiret, and E. Garin, 188Re-SSS/Lipiodol: development of a potential treatment for HCC from bench to bedside, International Journal of Molecular Imaging, vol.2012, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00866975

M. L. Thakur, A. W. Segal, L. Louis, M. J. Welch, J. Hopkins et al., Indium-111-labeled cellular blood components: mechanism of labeling and intracellular location in human neutrophils, Journal of Nuclear Medicine, vol.18, issue.10, pp.1022-1026, 1977.

J. Yu, U. O. Häfeli, M. Sands, and Y. Dong, 90Y-oxineethiodol, a potential radiopharmaceutical for the treatment of liver cancer, Applied Radiation and Isotopes, vol.58, issue.5, pp.567-573, 2003.

T. Das, S. Chakraborty, H. D. Sarma, M. Venkatesh, and S. Banerjee, Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer, Nuclear Medicine Communications, vol.30, issue.5, pp.362-367, 2009.

S. Subramanian, T. Das, and S. Chakraborty, Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: A Preliminary Animal Study, Cancer Biotherapy and Radiopharmaceuticals, vol.25, issue.5, pp.539-543, 2010.

N. Lepareur, J. Edeline, N. Noiret, V. Ardisson, and E. Garin, Preparation and preliminary evaluation of 90Y-tropolonateLipiodol as a potential radiopharmaceutical for hepatocellular carcinoma therapy, European Journal of Nuclear Medicine and Molecular Imaging, vol.43, p.454, 2016.

A. Lopez, N. Noiret, E. Garin, and N. Lepareur, Mixed-ligand complexes of yttrium-90 dialkyldithiocarbamates with 1,10-phenanthroline as a possible agent for therapy of hepatocellular carcinoma, Applied Radiation and Isotopes, vol.94, pp.241-246, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01069619

P. Y. Mu, X. L. Jiang, and J. Chen, Research on extracted 90Y with P204 in lipiodol for liver cancer, Journal of Radioanalytical and Nuclear Chemistry, vol.272, issue.3, pp.669-671, 2007.

M. Andreeff, G. Wunderlich, K. Behge, T. Schönmuth, and J. Kotzerke, -radiation exposure with 188Re-labelled pharmaceuticals, Nuklearmedizin / Nuclear Medicine, vol.44, issue.3, pp.94-98, 2005.

A. Rimpler, I. Barth, and P. Ferrari, Extremity exposure in nuclear medicine therapy with 90Y-labelled substances -Results of the ORAMED project, Radiation Measurements, vol.46, issue.11, pp.1283-1286, 2011.

L. Uccelli, M. Pasquali, A. Boschi, M. Giganti, and A. Duatti, Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma, Nuclear Medicine and Biology, vol.38, issue.2, pp.207-213, 2011.

N. Lepareur, V. Ardisson, and N. Noiret, Automation of labelling of Lipiodol with high-activity generator-produced 188Re, Applied Radiation and Isotopes, vol.69, issue.2, pp.426-430, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00752790

A. Mukherjee, S. Subramanian, R. Ambade, B. Avhad, A. Dash et al., Development of semiautomated module for preparation of 131I labeled lipiodol for liver cancer therapy, Cancer Biotherapy and Radiopharmaceuticals, vol.32, issue.1, pp.33-37, 2017.

N. Lepareur, S. Laffont, V. Ardisson, N. Noiret, and E. Garin, Reduction of -radiation exposure during preparation of 188Re-labelled Lipiodol for hepatocellular carcinoma treatment, Nuclear Medicine Communications, vol.33, issue.2, pp.205-208, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00867028

J. Raoul, P. Bourguet, and J. Bretagne, Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases, Radiology, vol.168, issue.2, pp.541-545, 1988.

C. H. Park, J. H. Suh, H. S. Yoo, J. T. Lee, and D. I. Kim, Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma. Therapeutic feasibility study, Clinical Nuclear Medicine, vol.11, issue.7, pp.514-517, 1986.

H. Ahmadzadehfar, A. Sabet, K. Wilhelm, H. J. Biersack, and J. Risse, Iodine-131-lipiodol therapy in hepatic tumours, Methods, vol.55, issue.3, pp.246-252, 2011.

E. Oger, A. Lavenu, E. Bellissant, E. Garin, and E. Polard, Metaanalysis of interstitial pneumonia in studies evaluating iodine-131-labeled lipiodol for hepatocellular carcinoma using exact likelihood approach, Pharmacoepidemiology and Drug Safety, vol.20, issue.9, pp.956-963, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00740165

F. X. Sundram, S. W. Yu, and J. M. Jeong, 188Rhenium-TDD-lipiodol in treatment of inoperable primary hepatocellular carcinoma -A case report, Annals, Academy of Medicine, vol.30, issue.5, pp.542-545, 2001.

K. Delaunay, E. Garin, and Y. Rolland, Biodistribution and dosimetry assessments for hepatocellular carcinoma treated with 188Re-SSS Lipiodol: Preliminary results of the phase 1 trial Lip Re 1, Journal of Nuclear Medicine, vol.59, issue.1, p.602, 2018.

G. H. Keng, F. X. Sundram, and S. W. Yu, Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates, Annals, Academy of Medicine, vol.31, issue.3, pp.382-386, 2002.

F. Sundram, T. C. Chau, P. Onkhuudai, P. Bernal, and A. K. Padhy, Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.31, issue.2, pp.250-257, 2004.

B. Lambert, K. Bacher, and L. Defreyne, 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: An activity escalation study, European Journal of Nuclear Medicine and Molecular Imaging, vol.33, issue.3, pp.344-352, 2006.

B. Lambert, K. Bacher, and L. Defreyne, 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: A phase I clinical trial, Journal of Nuclear Medicine, vol.46, issue.1, pp.60-66, 2005.

B. Lambert, K. Bacher, and K. De-keukeleire, 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: A feasibility study in patients with advanced cirrhosis, Journal of Nuclear Medicine, vol.46, issue.8, pp.1326-1332, 2005.

A. Kumar, C. Bal, and D. N. Srivastava, Transarterial radionuclide therapy with Re-188-HDD-lipiodol in case of unresectable hepatocellular carcinoma with extensive portal vein thrombosis, European Journal of Radiology Extra, vol.56, issue.2, pp.55-59, 2005.

A. Kumar, D. N. Srivastava, and C. Bal, Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil, Journal of Vascular and Interventional Radiology, vol.17, issue.1, pp.157-161, 2006.

A. Kumar, C. Bal, and D. N. Srivastava, Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol, European Journal of Gastroenterology & Hepatology, vol.18, issue.2, pp.219-223, 2006.

K. De-ruyck, B. Lambert, and K. Bacher, Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma, Journal of Nuclear Medicine, vol.45, issue.4, pp.612-618, 2004.

P. Bernal, J. Raoul, and G. Vidmar, Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-Sponsored Multination Study, International Journal of Radiation Oncology Biology Physics, vol.69, issue.5, pp.1448-1455, 2007.

P. Bernal, J. Raoul, and J. Stare, International atomic energy agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study, Seminars in Nuclear Medicine, vol.38, issue.2, pp.40-45, 2008.

A. Kumar, D. N. Srivastava, and T. T. Chau, Inoperable hepatocellular carcinoma: Transarterial 188Re HDD-labeled iodized oil for treatment -Prospective multicenter clinical trial, Radiology, vol.243, issue.2, pp.509-519, 2007.

R. Furtado, M. Crawford, and C. Sandroussi, Systematic review and meta-analysis of adjuvant I131 lipiodol after excision of hepatocellular carcinoma, Annals of Surgical Oncology, vol.21, issue.8, pp.2700-2707, 2014.

B. Brans, R. A. Dierckx, and F. D. Winter, The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: A pilot study, Cancer Biotherapy and Radiopharmaceuticals, vol.16, issue.4, pp.333-338, 2001.

J. Raoul, M. Messner, E. Boucher, J. Bretagne, J. Campion et al., Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol, British Journal of Surgery, vol.90, issue.11, pp.1379-1383, 2003.

B. Lambert, M. Praet, and P. Vanlangenhove, Radiolabeled lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: Pathology of the explant livers and clinical outcome, Cancer Biotherapy and Radiopharmaceuticals, vol.20, issue.2, pp.209-214, 2005.

T. De-baere, Y. Arai, and R. Lencioni, Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion, CardioVascular and Interventional Radiology, vol.39, issue.3, pp.334-343, 2016.

S. Herber, G. Otto, and J. Schneider, Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma, CardioVascular and Interventional Radiology, vol.30, issue.6, pp.1156-1165, 2007.

J. H. Risse, F. Grünwald, H. Strunk, R. Kleinschmidt, H. Bender et al., I-131-Lipiodol therapy in liver neoplasms, Hybridoma, vol.18, issue.1, pp.83-85, 1999.

J. R. Novell, A. J. Green, A. J. Hilson, G. Dusheiko, R. Dick et al., Selective Radionuclide Localisation in Primary Liver Tumours, HPB Surgery, vol.7, p.16, 1994.

F. Giammarile, L. Bodei, and C. Chiesa, EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds, European Journal of Nuclear Medicine and Molecular Imaging, vol.38, issue.7, pp.1393-1406, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00814020

G. Stansby, S. Bhattacharya, A. J. Hilson, D. M. Lane, and K. E. Hobbs, Localization of Lipiodol-radioiodine in hepatic metastases from renal cell carcinoma, British Journal of Radiology, vol.67, issue.800, pp.822-824, 1994.

R. A. Al-mufti, R. B. Pedley, and D. Marshall, In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines, British Journal of Cancer, vol.79, issue.11-12, pp.1665-1671, 1999.